Physician profile
Mark R Cervi
NPI 1700846672
$5,086.14
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,530 · 2020: $950 · 2021: $2,152 · 2022: $455.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $655.37 | 2019-2021 | |
| Amgen INC. | $628.35 | 2019-2022 | |
| Glaxosmithkline, LLC. | $453.63 | 2019-2022 | |
| Abbvie INC. | $380.41 | 2019-2022 | |
| Lilly USA, LLC | $283.78 | 2019-2021 | |
| Novo Nordisk INC | $248.53 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.49 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $208.89 | 2021-2022 | |
| Pfizer INC. | $204.56 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $201.38 | 2019-2022 | |
| Akcea Therapeutics, INC. | $151.68 | 2019-2021 | |
| Eisai INC. | $116.79 | 2020-2021 | |
| Boston Scientific Corporation | $114.97 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $113.15 | 2019 | |
| Esperion Therapeutics, INC. | $111.32 | 2020-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $97.22 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $93.03 | 2021 | |
| Astellas Pharma US INC | $81.15 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $75.07 | 2019-2021 | |
| Grifols USA, LLC | $63.00 | 2019 | |
| Amarin Pharma, INC. | $62.70 | 2021-2022 | |
| Acerus Pharmaceuticals Corporation | $50.24 | 2022 | |
| Dynavax Technologies Corporation | $46.66 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $45.10 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $43.29 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $43.11 | 2019 | |
| Abbott Laboratories | $38.60 | 2022 | |
| Gilead Sciences, INC. | $37.03 | 2019 | |
| Aytu Biopharma, INC. | $36.47 | 2019 | |
| Allergan, INC. | $36.21 | 2019 | |
| Clarus Therapeutics INC. | $33.45 | 2021 | |
| Janssen Pharmaceuticals, INC | $28.42 | 2021 | |
| Phadia US INC. | $16.98 | 2021 | |
| Antares Pharma, INC. | $16.47 | 2021 | |
| Dexcom, INC. | $15.31 | 2020 | |
| Currax Pharmaceuticals LLC | $13.49 | 2019 | |
| Mylan Specialty L.P. | $12.95 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.89 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cervi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.